GET DAILY SIGNALSImageneBio (IMA) Stock Slides -10% Over 30 Days on Thin Volume and Mixed Analyst Views
Key Takeaways
- ImageneBio (IMA) shares declined roughly 10% over the trailing 30 days, falling from a closing price of about $4.60 to near $4.14.
- The pullback extends a longer slide: the stock is down roughly 27% over the trailing three months and trades near the bottom of its 52-week range of $3.88 to $8.84.
- No single clinical catalyst drove the move; instead, low trading volume, a limited near-term data calendar, and sharply divergent analyst views weighed on sentiment.
- The investment case centers on olevaprubart (formerly IMG-007), a non-T-cell-depleting anti-OX40 monoclonal antibody in a Phase 2b atopic dermatitis trial.
- Analyst opinion remains split, with H.C. Wainwright holding a Buy rating and a $28 price target while Wedbush maintains a Sell rating and a $2 target.
- For additional detail on this ticker, explore ImageneBio's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading systems approach tickers like IMA.
Company Background and Market Position
ImageneBio, Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing treatments for immunological, autoimmune, and inflammatory diseases. The company was formed in July 2025 through a reverse merger between Ikena Oncology and Inmagene Biopharmaceuticals, completed alongside a concurrent $75 million private placement, after which the combined entity adopted the ImageneBio name.
The company's lead program is olevaprubart (formerly IMG-007), a receptor-targeting, non-T-cell-depleting anti-OX40 monoclonal antibody engineered with a silenced antibody-dependent cellular cytotoxicity function and an approximately five-week half-life. ImageneBio has completed Phase 1b/2a proof-of-concept studies in atopic dermatitis and alopecia areata and is now conducting the Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis. As a pre-revenue, single-asset developer with a market capitalization near $46 million, the stock is closely followed for clinical progress, cash runway, and any safety or efficacy signals from its OX40 program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, IMA shares moved from a closing price of approximately $4.60 to about $4.14, a decline of roughly 10%. The slide was not a straight line: the stock fell sharply in early October, briefly touched a 52-week low of $3.88 in late October, and then recovered modestly into the low-$4.00 range on thin trading volume.
The 30-day move is part of a broader multi-month downtrend. Roughly three months earlier, shares were trading near $5.69; the decline to $4.14 represents a drop of about 27% over the trailing quarter. This longer pullback reflects persistent selling pressure in a low-liquidity micro-cap name, with the stock holding near the lower end of its 52-week range of $3.88 to $8.84.
Factors Behind the Recent 30-Day Decline
The recent decline was driven less by a single event than by a combination of technical, liquidity, and sentiment factors. As a clinical-stage company with no approved products or material revenue, IMA is highly sensitive to changes in risk appetite, and its next major clinical data readout is not expected until 2027. That leaves the stock without an obvious near-term catalyst to support buying interest.
Trading volume has remained thin, amplifying day-to-day price swings. A sharp single-day decline in early October on elevated volume pushed shares below the $4.50 level, and the stock subsequently drifted toward its 52-week low before a modest rebound. Divergent analyst views also contributed to uncertainty: H.C. Wainwright reaffirmed a Buy rating with a $28 price target, while Wedbush has maintained a Sell rating with a $2 target, reflecting a wide gap in how market participants value the lead program's long-term potential against the risks of lengthy clinical development.
Quarter-Long Trends and Broader Pressures
Over the trailing quarter, IMA has trended steadily lower from roughly $5.69 to about $4.14. The decline followed the company's second-quarter 2026 financial results in early August and a series of regulatory and corporate updates that did not materially change the clinical timeline. The company also disclosed a $200 million mixed securities shelf and registered shares for sale by certain existing holders, which can weigh on sentiment for micro-cap equities even when the company itself is not selling.
The larger narrative is one of a post-merger biotech in an extended de-rating phase. Since the reverse merger, the stock has faced the typical pressures of a development-stage company: ongoing operating losses, a limited catalyst calendar, and reliance on a single asset. With roughly $135.3 million in cash and marketable securities reported at the end of 2025, the company's financial runway is a key point of focus, but investor enthusiasm has remained subdued ahead of the ADAPTIVE trial readout. From what I see, this extended period without near-term data leaves the shares vulnerable to sentiment shifts.
What Investors Should Watch Next
The most important catalyst for IMA is the ADAPTIVE Phase 2b trial of olevaprubart in moderate-to-severe atopic dermatitis, with topline data expected in 2027. Progress on enrollment, any interim safety updates, and presentations at dermatology conferences will be closely watched. Beyond the lead program, investors should monitor the company's cash burn and runway, quarterly earnings updates, and any changes to analyst ratings or price targets, given the wide spread between current bullish and bearish views.
Broader factors will also matter, including sentiment toward the biotechnology sector, interest-rate conditions that influence risk appetite, and competitive developments in the OX40/OX40L space as larger pharmaceutical companies advance their own programs. As with any clinical-stage developer, the stock carries meaningful risk tied to trial outcomes and regulatory timelines, and investors should evaluate these factors within the context of their own objectives. I’m watching this closely as the 2027 readout approaches.
Exploring AI-Driven Trading Approaches
In my own research process, I often turn to Tickeron’s AI tools to gain additional perspective on how systematic strategies are handling names like this. The platform’s AI Trading Bots section offers a range of data-driven approaches that can complement traditional fundamental analysis, helping to identify patterns across different timeframes and market conditions. It provides a useful way to compare performance metrics without relying solely on discretionary judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMA in upward trend: price may jump up because it broke its lower Bollinger Band on October 08, 2026
IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 40 cases where IMA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMA's RSI Indicator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where IMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for IMA just turned positive on October 23, 2026. Looking at past instances where IMA's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 91 of 112 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.331) is normal, around the industry mean (3.498). P/E Ratio (-0.876) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement